Atrandi Biosciences Enhances Executive Team to Drive International Growth of Its Innovative Single-Cell Technology
Atrandi Biosciences has expanded its executive and governance leadership team with the appointment of Sam Ropp as Chief Commercial Officer and Susan Tousi as Chairman of the Board of Directors. The company said the additions come at a pivotal stage in its growth strategy as it works to accelerate the worldwide adoption of its proprietary Semi-Permeable Capsule (SPC) technology platform for single-cell and multiomics research applications.
The appointments reflect Atrandi’s broader ambition to strengthen its commercial infrastructure and expand the reach of its capsule-based single-cell workflow technology, which is designed to overcome several limitations associated with conventional droplet-based systems. The company believes the platform can help researchers perform more sophisticated molecular biology workflows at single-cell resolution while maintaining experimental flexibility and scalability.
Atrandi Biosciences has positioned its SPC technology as a next-generation approach for researchers seeking to conduct complex multi-step workflows involving genomics, transcriptomics, proteomics, and other multiomic analyses. Unlike traditional droplet technologies that may limit workflow flexibility, the company’s capsule-based system is designed to support sequential biochemical reactions while preserving the identity of individual cells throughout the process.
Commenting on the leadership additions, Juozas Nainys, Chief Executive Officer of Atrandi Biosciences, said the experience both executives bring will help the company expand its impact within the global life sciences market.
According to Nainys, the organization is focused on making advanced single-cell experimentation more accessible and practical for routine laboratory use. He noted that both leaders bring substantial expertise in commercial execution, operational scaling, and strategic development, areas considered essential as Atrandi transitions from technology development toward broader commercialization.
Nainys added that Dr. Ropp’s background in building commercial organizations around innovative life science technologies, combined with Tousi’s experience guiding large-scale business growth and technology adoption, would support the company’s efforts to introduce SPC technology to a broader scientific community.
As Chief Commercial Officer, Dr. Ropp will oversee Atrandi’s worldwide commercial operations, including sales, marketing, customer support, field applications, and strategic partnerships. His role will involve building the commercial framework needed to expand customer adoption across research institutions, biotechnology companies, and translational medicine organizations.
Dr. Ropp joins Atrandi with more than 20 years of experience in the life sciences and biotechnology sectors, particularly in scaling emerging technology platforms and developing commercialization strategies for advanced research tools. Throughout his career, he has held senior leadership positions at several major companies in the genomics and analytical technology industries.
Prior to joining Atrandi, Dr. Ropp held leadership roles at Singular Genomics, 10x Genomics, BD, Molecular Devices, and Bio-Rad Laboratories. During his tenure at these organizations, he contributed to the commercialization and expansion of several advanced life science platforms, including technologies that became widely adopted within the single-cell analysis market.
Atrandi noted that Dr. Ropp’s experience spans both early-stage technology introduction and large-scale global commercialization, giving him a broad understanding of how scientific innovations transition from niche research tools into mainstream laboratory technologies. His work has frequently focused on helping researchers translate sophisticated scientific capabilities into scalable and user-friendly workflows.
Speaking about his new role, Dr. Ropp emphasized the growing opportunity within single-cell biology to move beyond isolated or single-modality experiments toward more integrated multiomic approaches that can provide deeper biological insights.
He explained that existing workflow limitations have historically constrained scientists’ ability to fully explore cellular biology at high resolution. According to Dr. Ropp, Atrandi’s SPC platform introduces a new level of workflow flexibility that could allow researchers to design more advanced experiments than what has typically been possible using traditional droplet-based methods.
Dr. Ropp also highlighted the importance of building strong commercial partnerships and infrastructure to ensure the technology becomes broadly accessible to laboratories worldwide. He said Atrandi’s next stage of growth will focus not only on technology development but also on establishing the operational capabilities needed to support widespread customer adoption.
In addition to strengthening its executive team, Atrandi Biosciences has also appointed Susan Tousi as Chairman of the Board of Directors. Tousi brings more than three decades of leadership experience across biotechnology, diagnostics, imaging, and genomics industries.
Throughout her career, Tousi has held executive leadership and board-level positions at some of the most influential companies in the life sciences sector. She is widely recognized for her expertise in technology innovation, product development, and commercial strategy, particularly in areas involving genomic analysis and diagnostic technologies.
Tousi currently serves as Chief Executive Officer of Delfi Diagnostics. Before joining Delfi Diagnostics, she held senior executive positions at Illumina, where she served as Chief Commercial Officer as well as Senior Vice President and Chief Product Officer.
During her time at Illumina, Tousi played a key role in the development and commercialization of genomic technologies that contributed to the company’s expansion into a multi-billion-dollar global business. Her contributions to engineering and technological innovation earned her induction into the National Academy of Engineering, one of the highest professional distinctions awarded to engineers.
Atrandi believes Tousi’s strategic guidance and industry experience will help the company navigate its next phase of growth as it seeks broader market penetration and expanded adoption across both research and translational applications.
Tousi stated that demand continues to increase for flexible and scalable single-cell analysis technologies capable of supporting more advanced biological research. She noted that Atrandi’s SPC platform offers meaningful advantages compared with many conventional droplet-based and alternative single-cell systems currently available in the market.
According to Tousi, the company is well positioned to capitalize on evolving research needs as scientists increasingly seek technologies capable of integrating multiple molecular workflows into a single experimental framework. She said she looks forward to supporting Atrandi’s leadership team as the organization works to scale operations strategically and expand its technological footprint globally.
At the center of Atrandi’s strategy is its patented Semi-Permeable Capsule technology, which the company describes as a new category of infrastructure for single-cell molecular biology workflows. The technology is built around microscopic capsules composed of a liquid interior core enclosed by a thin hydrogel shell with selective permeability properties.
The design allows small molecules, including enzymes, salts, primers, antibodies, and buffers, to diffuse freely through the shell while larger structures such as cells, genomic DNA, and molecular complexes remain encapsulated inside. This selective permeability enables researchers to carry out multiple sequential biochemical reactions without losing the identity of individual cells.
The company says this capability is particularly valuable for multi-step workflows that require washing, reagent exchange, or staged molecular reactions, processes that can be difficult to perform efficiently using some existing single-cell technologies.
By combining characteristics traditionally associated with both well-based and droplet-based systems, Atrandi aims to provide researchers with a platform capable of supporting bulk-like molecular reactions while still preserving single-cell resolution and throughput. The company believes this hybrid approach could enable a broader range of experimental designs and expand the possibilities for multiomic discovery.
As the field of single-cell biology continues to evolve rapidly, Atrandi Biosciences is positioning SPC technology as a flexible foundation for future research applications spanning genomics, diagnostics, translational medicine, and advanced biological discovery. With the addition of experienced leaders in commercial operations and strategic governance, the company appears focused on accelerating the transition of its technology from emerging innovation to widely adopted research infrastructure.
About Atrandi Biosciences
Atrandi Biosciences is a life science tools company advancing single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology, enabling scalable multi-step workflows that preserve single-cell identity across sequential chemistry. Headquartered in Vilnius, Lithuania, Atrandi supports researchers worldwide with commercially available SPCs, workflow kits, and instruments. Its name, meaning “you discover” in Lithuanian, reflects the company’s purpose: helping scientists uncover what biology keeps hidden. For more information, visit www.atrandi.com.
